These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 32531951)

  • 1. Androgen Deprivation Induces Reprogramming of Prostate Cancer Cells to Stem-Like Cells.
    Sánchez BG; Bort A; Vara-Ciruelos D; Díaz-Laviada I
    Cells; 2020 Jun; 9(6):. PubMed ID: 32531951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
    Alberti C
    G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells.
    Zhang XQ; Kondrikov D; Yuan TC; Lin FF; Hansen J; Lin MF
    Oncogene; 2003 Oct; 22(43):6704-16. PubMed ID: 14555984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cells.
    Moritz T; Venz S; Junker H; Kreuz S; Walther R; Zimmermann U
    Tumour Biol; 2016 Aug; 37(8):10435-46. PubMed ID: 26846108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Localization of immunoreactive HIF-1alpha and HIF-2alpha in neuroendocrine cells of both benign and malignant prostate glands.
    Monsef N; Helczynski L; Lundwall A; Påhlman S;
    Prostate; 2007 Aug; 67(11):1219-29. PubMed ID: 17562539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells.
    Mabjeesh NJ; Willard MT; Frederickson CE; Zhong H; Simons JW
    Clin Cancer Res; 2003 Jul; 9(7):2416-25. PubMed ID: 12855613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AMPK/SIRT1 signaling through p38MAPK mediates Interleukin-6 induced neuroendocrine differentiation of LNCaP prostate cancer cells.
    Natani S; Dhople VM; Parveen A; Sruthi KK; Khilar P; Bhukya S; Ummanni R
    Biochim Biophys Acta Mol Cell Res; 2021 Sep; 1868(10):119085. PubMed ID: 34171447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib.
    Bort A; Sánchez BG; Mateos-Gómez PA; Vara-Ciruelos D; Rodríguez-Henche N; Díaz-Laviada I
    Mol Oncol; 2019 May; 13(5):1311-1331. PubMed ID: 30959553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
    Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Up-Regulated Expression of LAMP2 and Autophagy Activity during Neuroendocrine Differentiation of Prostate Cancer LNCaP Cells.
    Morell C; Bort A; Vara-Ciruelos D; Ramos-Torres Á; Altamirano-Dimas M; Díaz-Laviada I; Rodríguez-Henche N
    PLoS One; 2016; 11(9):e0162977. PubMed ID: 27627761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
    Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
    Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The β
    Braadland PR; Ramberg H; Grytli HH; Urbanucci A; Nielsen HK; Guldvik IJ; Engedal A; Ketola K; Wang W; Svindland A; Mills IG; Bjartell A; Taskén KA
    Mol Cancer Res; 2019 Nov; 17(11):2154-2168. PubMed ID: 31395667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of prostate cancer spheres from a prostate cancer cell line after phenethyl isothiocyanate treatment and discovery of androgen-dependent reversible differentiation between sphere and neuroendocrine cells.
    Chen Y; Cang S; Han L; Liu C; Yang P; Solangi Z; Lu Q; Liu D; Chiao JW
    Oncotarget; 2016 May; 7(18):26567-79. PubMed ID: 27034170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enrichment of putative prostate cancer stem cells after androgen deprivation: upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines.
    Seiler D; Zheng J; Liu G; Wang S; Yamashiro J; Reiter RE; Huang J; Zeng G
    Prostate; 2013 Sep; 73(13):1378-90. PubMed ID: 23728788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model.
    Hobisch A; Hoffmann J; Lambrinidis L; Eder IE; Bartsch G; Klocker H; Culig Z
    Urol Int; 2000; 65(2):73-9. PubMed ID: 11025427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
    Begemann D; Wang Y; Yang W; Kyprianou N
    Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
    Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
    Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen deprivation modulates gene expression profile along prostate cancer progression.
    Volante M; Tota D; Giorcelli J; Bollito E; Napoli F; Vatrano S; Buttigliero C; Molinaro L; Gontero P; Porpiglia F; Tucci M; Papotti M; Berruti A; Rapa I
    Hum Pathol; 2016 Oct; 56():81-8. PubMed ID: 27342909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
    Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
    Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.